China’s National Medical Products Administration (NMPA) is seeking public comments on new regulations it is drafting on drug registration, drug distribution, and manufacturing. The new regulations, updated in October by the Ministry of Justice, reflect changes made to the Drug Administration Law... Read More
One year after Japan tightened its drug pricing system in a bid to make cutting-edge treatments more affordable, the restrictions threaten to slow drug sales to the country, a pharmaceutical industry leader warned last month. Under the new policy, announced in 2018,... Read More
Despite renewed government efforts to bring South Korea’s historically elevated rate of tuberculosis under control, the nation still has the highest incidence rate of the disease among the world’s wealthiest countries – nations that belong to the 34-member Organization for Economic Cooperation and... Read More
China’s ambitious campaign to expand healthcare coverage and access to innovative drugs is making its pharmaceutical market an increasingly key source of growth for foreign firms. But even as the more than $135 billion pharmaceutical markets in the Asian giant surpasses that... Read More
Spending on cancer drugs is dominating health spending in China, with hospitals in 2018 purchasing more cancer and immunomodulatory drugs than anti-infective drugs for the first time ever. According to data from the China Pharmaceutical Association (CPA), anti-tumor and immunomodulatory treatments represented... Read More
Fueled by high sugar diets, processed food, misinformation and a dearth of early intervention, the prevalence of Type 2 diabetes is a persistent public health crisis in Southeast Asia. One of every 14 people in Indonesia, Malaysia, Singapore, and Thailand has some... Read More
This article was originally published on Medtech Intelligence. Precision medicine, an emerging toolkit of ways to better understand the complex mechanisms underlying a patient’s health, disease, or condition, and to better predict which treatments will be most effective, has grown unevenly outside... Read More
Moving to make it easier for innovative drug therapies to enter the Chinese market, the country’s National Healthcare Security Administration (NHSA) announced in August 2019 it will make 148 new drugs eligible for insurance reimbursement. Altogether, patients will be able to seek... Read More
Six months after Collategene became the first gene therapeutic drug cleared for use in Japan, the country’s health insurance system announced in September 2019 it would be placed on the list of pharmaceuticals approved for coverage. The drug, which introduces genes that... Read More
Stymied by what they say is overzealous regulation, India’s’ drug companies are increasingly lobbying the government to reduce oversight of clinical trials, ease limits on new pharmaceutical ventures, and reduce regulations on new drugs. Pharma firms in India are big business. Currently... Read More